8-K: Protagenic Therapeutics Implements 1-for-14 Reverse Stock Split to Meet Nasdaq Minimum Bid Price

Protagenic Therapeutics enacted a 1-for-14 reverse stock split, effective May 5, 2025, to comply with Nasdaq's minimum bid price requirement.

Summary

• Protagenic Therapeutics implemented a 1-for-14 reverse stock split of its common stock.
• The reverse stock split became effective on May 5, 2025, at 12:01 a.m. Eastern Time.
• The primary reason for the reverse stock split is to comply with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)).
• Every fourteen shares of outstanding common stock were combined into one share.
• The number of authorized shares and par value per share remain unchanged.
• Adjustments were made to the exercise price and number of shares issuable under outstanding stock options, restricted stock units, and warrants.
• Fractional shares resulting from the split will be rounded up to the next whole share.
• The company's common stock will continue to trade on the Nasdaq Capital Market under the ticker symbol PTIX, but with a new CUSIP number (74365N301).

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the reverse stock split is a necessary step to maintain Nasdaq listing, it often reflects underlying financial challenges and can be perceived negatively by investors.

Positives

• The reverse stock split helps the company maintain its Nasdaq listing by complying with the minimum bid price rule.

Negatives

• Reverse stock splits are often viewed negatively by investors as they can indicate financial distress or an attempt to artificially inflate the stock price.

Risks

• The reverse stock split may not be sufficient to maintain compliance with Nasdaq listing requirements if the stock price continues to decline.
• Investor perception of the reverse stock split could negatively impact the company's stock price.

Future Outlook

The company expects its common stock to open for trading on a post-split basis on Nasdaq as of the commencement of trading on May 5, 2025.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Other companies in similar situations may consider this approach to maintain compliance.

Comparison to Industry Standards

• Many small-cap and micro-cap companies facing similar challenges with Nasdaq compliance have implemented reverse stock splits.
• The specific ratio of the reverse split (1-for-14 in this case) is determined by the company's board based on the need to meet the minimum bid price requirement while considering the potential impact on shareholders.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the proportionate ownership remains the same.
• The reverse stock split aims to maintain the company's listing on Nasdaq, which could benefit shareholders in the long term.

Next Steps

• Stockholders of record will receive information from the company's transfer agent regarding their common stock ownership post-Reverse Stock Split.

Key Dates

Keywords

reverse stock split, Protagenic Therapeutics, PTIX, Nasdaq, minimum bid price, compliance